Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: A systematic review and network meta-analysis

Systematic Reviews

Volumn 5, Issue 1, 2016, Pages

  Singh, Jasvinder A ^a,b,c   Hossain, Alomgir ^d   Kotb, Ahmed ^d   Wells, George A ^d  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cyclophosphamide; Glucocorticoids; Immunosuppressive drugs; Lupus; Lupus nephritis; Mycophenolate mofetil; Network meta analysis; Renal relapse; Renal remission; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; GLUCOCORTICOID;

AMENORRHEA; ARTICLE; COMPARATIVE EFFECTIVENESS; CYTOPENIA; HUMAN; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; OVARY INSUFFICIENCY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; META ANALYSIS; NETWORK META-ANALYSIS; ODDS RATIO; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; NETWORK META-ANALYSIS; ODDS RATIO; TREATMENT OUTCOME;

EID: 84987653531     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-016-0328-z     Document Type: Article

References (37)

1. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis & Rheumatism. 2013;65(3):753-63.
2. Odutola J, Ward MM. Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Curr Opin Rheumatol. 2005;17(2):147-52.
3. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus. 1999;8(3):197-209.
4. Centers for Disease Control and Prevention (CDC). Trends in deaths from systemic lupus erythematosus--United States, 1979-1998. MMWR Morb Mortal Wkly Rep. 2002;51(17):371-4.
5. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006;65(11):1500-5.
6. Institute of Medicine. 100 initial priority topics for comparative effectiveness research. http://www.nationalacademies.org/hmd/Reports/2009/ComparativeEffectivenessResearchPriorities.aspx alone list of 100 cer priorities - for web.pdf. National Academies Press; 2009.
7. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-808.
8. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2012;12:CD002922.
9. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
10. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One. 2012;7(4):e34785.
11. Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54.
12. Ross S. Composite outcomes in randomized clinical trials: arguments for and against. Am J Obstet Gynecol. 2007;196(2):119 e1-6.
13. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. Rockville: Department of Health and Human Services; 2012. http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318.
14. Cassaday RD, Malik JT, Chang JE. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):289-92.
15. Singh JA, Noorbaloochi S, Tucker MD. Belimumab for systemic lupus erythematosus (protocol). Cochrane Database Syst Rev. 2013. DOI: 10.1002/14651858.CD010668
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
17. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12.
18. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? ClinExpNephrol. 2010;14(3):214-21.
19. Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al SA, Alam A, et al. Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transpl. 2011;22(5):935-40.
20. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-9.
21. Higgins JP, Altman DG, Sterne JA. Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). In: The Cochrane Collaboration. Higgins JP, Green S, editors. 2011. Available from http://handbook.cochrane.org/.
22. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313-24.
23. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-44.
24. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-24.
25. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kyrgiou M, et al. NICE DSU Technical Support Document 2: Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.pp. 1-96. [cited 2012 June 13]. Available from: http://www.nicedsu.org.uk/TSD6%20Software.final.08.05.12.pdf.
26. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kyrgiou M, et al. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, meta-regression, bias and bias-adjustment May 2011. pp. 1-24. [cited 2012 June 13]. Available from: http://www.nicedsu.org.uk/TSD6%20Software.final.08.05.12.pdf.
27. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861-81.
28. Turner RM, Thompson SG, Spiegelhalter DJ. Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials. Clin Trials. 2005;2(2):108-18.
29. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual. Version 1.4. 2003 [cited 2011 June 1]. Available from: http://www.mrc-bsu.cam.ac.uk/wp-content/uploads/manual14.pdf.
30. Ades AE, Welton NJ, Caldwell D, Price M, Goubar A, Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy. 2008;13 Suppl 3:12-22.
31. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kyrgiou M, et al. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 2011. pp 1-39[cited 2012 June 13]. Available from: http://www.nicedsu.org.uk/TSD6%20Software.final.08.05.12.pdf.
32. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
33. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos, II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152-160. doi: 10.1038/ki.2009.412.
34. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38(2):256-64. doi: 10.1053/ajkd.2001.26084.
35. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J. 2002;115(5):705-9.
36. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ, China Leflunomide Lupus Nephritis Study G. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008;17(7):638-44. doi: 10.1177/0961203308089408.
37. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-28.